
Cigna Pharmacy is owned by The Cigna Group (NYSE: CI), a publicly traded healthcare company headquartered in Bloomfield, Connecticut. The brand operates within Evernorth Health Services, The Cigna Group's pharmacy benefit division, which was formed after the $52 billion acquisition of Express Scripts in 2018. Evernorth generated approximately $7.0 billion in pre-tax adjusted income from operations in 2024. The Cigna Group reported $247.1 billion in total revenues for 2024.
Parent Company
Acquired
2018
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Cigna Pharmacy | The Cigna Group | Brand division |
Cigna Pharmacy was created in 2018 following The Cigna Group's acquisition of Express Scripts. Express Scripts, founded in 1986 in St. Louis, Missouri, had grown into the largest pharmacy benefit manager in the United States. By the time of the acquisition, Express Scripts managed prescription drug benefits for more than 100 million Americans and generated annual revenues exceeding $100 billion.
The Cigna Group announced the Express Scripts acquisition in March 2018 and completed the deal in December 2018. The transaction was valued at approximately $52 billion, including the assumption of about $15 billion in Express Scripts debt. The deal was the largest in the history of the healthcare insurance industry at the time. The acquisition combined Cigna's medical insurance business with Express Scripts' pharmacy benefit management platform, creating a company with initial combined revenues exceeding $100 billion.
Following the acquisition, The Cigna Group reorganized its operations. The company created the Evernorth Health Services segment in 2020 to house Express Scripts and related pharmacy businesses. Cigna Pharmacy was positioned as the consumer-facing pharmacy brand that connects Express Scripts' benefit management infrastructure with Cigna's health insurance plans. This integration allowed the company to offer coordinated medical and pharmacy benefits to employer clients.
In 2023, The Cigna Group rebranded its corporate name from Cigna Corporation to The Cigna Group. This rebranding reflected the company's dual structure: Evernorth Health Services for pharmacy and care delivery, and Cigna Healthcare for medical insurance. Cigna Pharmacy sits at the intersection of these two segments.
The Express Scripts integration was not without challenges. Combining two large organizations with different technology systems, corporate cultures, and operational processes required several years of work. The integration involved consolidating technology platforms, standardizing customer service operations, and aligning formulary management practices. By 2022, The Cigna Group reported that the integration was substantially complete.
In 2024 and 2025, Evernorth expanded its specialty pharmacy capabilities through Accredo, its specialty pharmacy brand. The division also grew its biosimilar dispensing business, offering lower-cost alternatives to biologic drugs. In 2024, Evernorth's pre-tax adjusted income from operations reached $7.0 billion, representing 9% year-over-year growth. The Cigna Group projected at least $7.2 billion in Evernorth pre-tax adjusted income for 2025.
The March 2025 sale of the Medicare business to HCSC affected Cigna Pharmacy's scope. While Evernorth continues to provide pharmacy benefit services to the divested Medicare plans under a four-year contract, Cigna Pharmacy's direct Medicare Part D operations transferred to HCSC. The brand now focuses primarily on commercial pharmacy benefit management and specialty pharmacy services.
What does The Cigna Group own?
The Cigna Group owns Cigna Healthcare (health insurance products including medical, dental, behavioral health, and vision plans), Express Scripts (pharmacy benefits management), Evernorth Health Services (specialty pharmacy and care coordination), Cigna Dental, Cigna Pharmacy, and Cigna Global Health Benefits. In 2025, the company sold its Medicare Advantage, Medicare Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation.
Is The Cigna Group publicly traded?
Yes, The Cigna Group is publicly traded on the New York Stock Exchange under ticker symbol CI. The company has been publicly traded since its formation in 1982 and is a component of the S&P 500 Index, ranked No. 13 on the Fortune 500.
Who founded The Cigna Group?
The Cigna Group was founded in 1982 through the merger of Connecticut General Life Insurance Company (founded 1865 in Hartford, Connecticut) and Insurance Company of North America (founded 1792 in Philadelphia, one of the oldest insurance companies in America). The company was renamed The Cigna Group in February 2023.
Where is The Cigna Group headquartered?
The Cigna Group is headquartered at 900 Cottage Grove Road, Bloomfield, Connecticut 06002, USA. The company operates in more than 30 markets and jurisdictions worldwide.
How many brands does The Cigna Group own?
The Cigna Group's principal brands are Cigna Healthcare, Express Scripts, and Evernorth Health Services. These umbrella brands cover health insurance, pharmacy benefits management, dental insurance, pharmacy services, and international health benefits.
Who owns The Cigna Group?
The Cigna Group is publicly owned with a dispersed shareholder base. Institutional investors hold the majority of shares, with no single controlling shareholder. Major institutional shareholders include Vanguard Group, BlackRock, and State Street Global Advisors, typical of S&P 500 companies.
What is The Cigna Group's revenue?
For FY2025, The Cigna Group reported total revenues of $274.9 billion, up 11% from $247.1 billion in FY2024. Shareholders' net income was $6.0 billion, or $22.18 per share. Adjusted income from operations was $8.0 billion, or $29.84 per share. For 2026, the company projects adjusted revenues of approximately $280 billion.
Has The Cigna Group made major changes recently?
Yes. In March 2025, Cigna completed the sale of its Medicare Advantage and related businesses to HCSC. In October 2025, Express Scripts announced a new rebate-free PBM model. In February 2026, Express Scripts reached a landmark settlement with the FTC over insulin pricing practices. The company also increased its quarterly dividend to $1.56 per share.
Cigna Pharmacy, through its parent company's Express Scripts operations, has faced several regulatory and legal challenges. The Federal Trade Commission's ongoing investigation into pharmacy benefit management practices is the most significant. In July 2024, the FTC published an interim staff report that criticized Express Scripts, CVS Caremark, and OptumRx for practices including steering patients to affiliated pharmacies, collecting rebates from drug manufacturers without fully passing savings to consumers, and using formulary design to favor higher-priced drugs. The Cigna Group disputed the report's findings and stated that its PBM services save clients and members money on prescription drugs.
In 2023, a class-action lawsuit was filed against Express Scripts alleging anticompetitive practices related to insulin pricing. The lawsuit claimed that Express Scripts and other PBMs negotiated rebates with insulin manufacturers that inflated list prices while PBMs retained a portion of the rebates. Similar lawsuits were filed against CVS Caremark and OptumRx. The litigation is ongoing as of 2025.
Express Scripts has also faced disputes with independent pharmacies over reimbursement rates. The National Community Pharmacists Association has criticized Express Scripts and other PBMs for reimbursement practices that independent pharmacies say are below their cost to acquire medications. Several states have passed laws regulating PBM reimbursement practices, and Express Scripts has challenged some of these laws in court.
In 2023, a data breach at a third-party vendor affected approximately 1.5 million Cigna customers. While the breach was not specific to pharmacy operations, it exposed patient information including names, dates of birth, and in some cases Social Security numbers. The Cigna Group offered affected customers free credit monitoring and implemented additional vendor security requirements.
The 2018 Express Scripts acquisition itself faced antitrust scrutiny. The Department of Justice reviewed the deal but ultimately approved it without requiring divestitures. Some consumer advocacy groups opposed the merger, arguing that vertical integration between health insurance and pharmacy benefit management could reduce competition. The American Medical Association and certain state insurance regulators expressed similar concerns during the review process.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Cigna | USA | 1982 | Mass market | United states | All Genders |
Market Positioning: Cigna Pharmacy competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by The Cigna Group, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Cigna Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Cigna Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Cigna Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.